Quick Answer
INOVIO PHARMACEUTICALS, INC. reported Total Revenue of $65.3 thousand for fiscal year 2025.
INOVIO PHARMACEUTICALS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $65.3K -70.0% |
$217.8K -73.8% |
$832.0K -91.9% |
$10.26M +478.2% |
$1.77M -76.1% |
$7.41M +80.2% |
| Revenue (ASC 606) | $65.3K -70.0% |
$217.8K -73.8% |
$832.0K -91.9% |
$10.26M +478.2% |
$1.77M -76.1% |
$7.41M +80.2% |
| Net Income | -$84.95M +20.8% |
-$107.25M +20.6% |
-$135.12M +51.7% |
-$279.82M +7.9% |
-$303.66M -82.5% |
-$166.41M -39.4% |
| Diluted EPS | -$1.81 +54.2% |
-$3.95 +35.1% |
-$6.09 +56.7% |
-$14.07 +19.4% |
-$17.45 -1530.8% |
-$1.07 +11.6% |
| Total Assets | $74.31M -34.4% |
$113.20M -33.8% |
$170.95M -51.0% |
$348.53M -29.7% |
$495.94M -8.1% |
$539.77M +275.0% |
| Cash and Equivalents | $44.27M -32.7% |
$65.81M +359.9% |
$14.31M -69.1% |
$46.33M -34.9% |
$71.14M -71.6% |
$250.73M +1029.6% |
| Stockholders Equity | $24.10M -64.8% |
$68.50M -41.6% |
$117.35M -47.2% |
$222.36M -44.4% |
$399.67M -13.3% |
$461.14M +13324.4% |
| R&D Expense | $54.21M -28.3% |
$75.62M -12.8% |
$86.68M -53.8% |
$187.65M -24.7% |
$249.24M +164.5% |
$94.25M +7.1% |
| Operating Income | -$86.82M +22.8% |
-$112.40M +21.9% |
-$143.94M +46.2% |
-$267.57M +11.2% |
-$301.22M -142.8% |
-$124.08M -11.7% |
| Shares Outstanding | 69.00M +91.1% |
36.10M +58.4% |
22.79M +8.1% |
21.09M -90.3% |
217.38M +16.3% |
186.85M +84.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | — | — |
| Revenue (ASC 606) | September 30, 2025 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$45.50M | -80.8% | -93.4% |
| Diluted EPS | September 30, 2025 | -$0.87 | +2.2% | -42.6% |
| Total Assets | September 30, 2025 | $69.39M | -35.2% | +1.7% |
| Cash and Equivalents | September 30, 2025 | $36.57M | +68.6% | +50.2% |
| Long-Term Debt | June 30, 2019 | $62.76M | — | +3.6% |
| Stockholders Equity | September 30, 2025 | -$7.72M | -110.5% | -127.1% |
| R&D Expense | September 30, 2025 | $13.33M | -28.8% | -8.2% |
| Operating Income | September 30, 2025 | -$21.21M | +22.4% | +8.1% |
- INOVIO PHARMACEUTICALS, INC. reported Total Revenue of $65.3 thousand for fiscal year 2025.
- INOVIO PHARMACEUTICALS, INC. showed a decrease of -70.0% in Total Revenue compared to the prior fiscal year.
- INOVIO PHARMACEUTICALS, INC. reported Revenue (ASC 606) of $65.3 thousand for fiscal year 2025.
- INOVIO PHARMACEUTICALS, INC. showed a decrease of -70.0% in Revenue (ASC 606) compared to the prior fiscal year.
- INOVIO PHARMACEUTICALS, INC. reported Net Income of -$84.95 million for fiscal year 2025.
- INOVIO PHARMACEUTICALS, INC. showed an increase of +20.8% in Net Income compared to the prior fiscal year.
- INOVIO PHARMACEUTICALS, INC. reported Diluted EPS of $1.81 per share (loss) for fiscal year 2025.
- INOVIO PHARMACEUTICALS, INC. showed an increase of +54.2% in Diluted EPS compared to the prior fiscal year.
- INOVIO PHARMACEUTICALS, INC. reported Total Assets of $74.31 million for fiscal year 2025.
- INOVIO PHARMACEUTICALS, INC. showed a decrease of -34.4% in Total Assets compared to the prior fiscal year.
- INOVIO PHARMACEUTICALS, INC. reported Cash and Equivalents of $44.27 million for fiscal year 2025.
- INOVIO PHARMACEUTICALS, INC. showed a decrease of -32.7% in Cash and Equivalents compared to the prior fiscal year.
- INOVIO PHARMACEUTICALS, INC. reported Stockholders Equity of $24.10 million for fiscal year 2025.
- INOVIO PHARMACEUTICALS, INC. showed a decrease of -64.8% in Stockholders Equity compared to the prior fiscal year.
- INOVIO PHARMACEUTICALS, INC. reported R&D Expense of $54.21 million for fiscal year 2025.
- INOVIO PHARMACEUTICALS, INC. showed a decrease of -28.3% in R&D Expense compared to the prior fiscal year.
- INOVIO PHARMACEUTICALS, INC. reported Operating Income of -$86.82 million for fiscal year 2025.
- INOVIO PHARMACEUTICALS, INC. showed an increase of +22.8% in Operating Income compared to the prior fiscal year.
- INOVIO PHARMACEUTICALS, INC. reported Shares Outstanding of 69.00 million shares for fiscal year 2025.
- INOVIO PHARMACEUTICALS, INC. showed an increase of +91.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: